Toll IL-1R8/single Ig IL-1-related receptor regulates psoriasiform inflammation through direct inhibition of innate IL-17A expression by γδ T cells

Journal of Immunology

Volumn 191, Issue 6, 2013, Pages 3337-3346

  Russell, Shane E ^a   Stefanska, Anna M ^a   Kubica, Malgorzata ^a   Horan, Rachel M ^a   Mantovani, Alberto ^b,c   Garlanda, Cecilia ^b   Fallon, Padraic G ^a   Walsh, Patrick T ^a  

^a OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR TYPE 8; INTERLEUKIN 17; INTERLEUKIN RECEPTOR; SINGLE IMMUNOGLOBULIN INTERLEUKIN 1 RELATED RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GAMMA DELTA T LYMPHOCYTE; HISTOPATHOLOGY; IMMUNOPATHOGENESIS; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; PSORIASIS;

ANIMALS; ARTHRITIS, PSORIATIC; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; INFLAMMATION; INTERLEUKIN-17; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RECEPTORS, INTERLEUKIN-1; T-LYMPHOCYTES;

EID: 84884235625     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300828     Document Type: Article

References (43)

1. Perera, G. K., P. Di Meglio, and F. O. Nestle. 2012. Psoriasis. Annu. Rev. Pathol. 7: 385-422.
2. Schön, M. P., and W. H. Boehncke. 2005. Psoriasis. N. Engl. J. Med. 352: 1899-1912.
3. Lowes, M. A., A. M. Bowcock, and J. G. Krueger. 2007. Pathogenesis and therapy of psoriasis. Nature 445: 866-873.
4. Ellis, C. N., D. C. Gorsulowsky, T. A. Hamilton, J. K. Billings, M. D. Brown, J. T. Headington, K. D. Cooper, O. Baadsgaard, E. A. Duell, T. M. Annesley, et al. 1986. Cyclosporine improves psoriasis in a double-blind study. JAMA 256: 3110-3116.
5. Nickoloff, B. J., and F. O. Nestle. 2004. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J. Clin. Invest. 113: 1664-1675.
6. Nestle, F. O., and C. Conrad. 2004. The IL-12 family member p40 chain as a master switch and novel therapeutic target in psoriasis. J. Invest. Dermatol. 123: xiv-xv.
7. Blauvelt, A. 2008. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J. Invest. Dermatol. 128: 1064-1067.
8. Wilson, N. J., K. Boniface, J. R. Chan, B. S. McKenzie, W. M. Blumenschein, J. D. Mattson, B. Basham, K. Smith, T. Chen, F. Morel, et al. 2007. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 8: 950-957.
9. Pantelyushin, S., S. Haak, B. Ingold, P. Kulig, F. L. Heppner, A. A. Navarini, and B. Becher. 2012. Rorgt+ innate lymphocytes and gd T cells initiate psoriasiform plaque formation in mice. J. Clin. Invest. 122: 2252-2256.
10. Cai, Y., X. Shen, C. Ding, C. Qi, K. Li, X. Li, V. R. Jala, H. G. Zhang, T. Wang, J. Zheng, and J. Yan. 2011. Pivotal role of dermal IL-17-producing gd T cells in skin inflammation. Immunity 35: 596-610.
11. Papp, K. A., C. Leonardi, A. Menter, J. P. Ortonne, J. G. Krueger, G. Kricorian, G. Aras, J. Li, C. B. Russell, E. H. Thompson, and S. Baumgartner. 2012. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366: 1181-1189.
12. Leonardi, C., R. Matheson, C. Zachariae, G. Cameron, L. Li, E. Edson-Heredia, D. Braun, and S. Banerjee. 2012. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366: 1190-1199.
13. Cua, D. J., J. Sherlock, Y. Chen, C. A. Murphy, B. Joyce, B. Seymour, L. Lucian, W. To, S. Kwan, T. Churakova, et al. 2003. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744-748.
14. Langrish, C. L., Y. Chen, W. M. Blumenschein, J. Mattson, B. Basham, J. D. Sedgwick, T. McClanahan, R. A. Kastelein, and D. J. Cua. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201: 233-240.
15. Leonardi, C. L., A. B. Kimball, K. A. Papp, N. Yeilding, C. Guzzo, Y. Wang, S. Li, L. T. Dooley, and K. B. Gordon; PHOENIX 1 study investigators. 2008. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 1). Lancet 371: 1665-1674.
16. Dinarello, C. A. 2009. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27: 519-550.
17. Debets, R., J. P. Hegmans, P. Croughs, R. J. Troost, J. B. Prins, R. Benner, and E. P. Prens. 1997. The IL-1 system in psoriatic skin: IL-1 antagonist sphere of influence in lesional psoriatic epidermis. J. Immunol. 158: 2955-2963.
18. Mee, J. B., M. J. Cork, F. S. di Giovine, G. W. Duff, and R. W. Groves., 2006. Interleukin-1:a key inflammatory mediator in psoriasis? Cytokine 33: 72-78.
19. Uribe-Herranz, M., L. H. Lian, K. M. Hooper, K. A. Milora, and L. E. Jensen. 2013. IL-1R1 signaling facilitates Munro's microabscess formation in psoriasiform imiquimod-induced skin inflammation. J. Invest. Dermatol. 133: 1541-1549.
20. Wald, D., J. Qin, Z. Zhao, Y. Qian, M. Naramura, L. Tian, J. Towne, J. E. Sims, G. R. Stark, and X. Li. 2003. SIGIRR, a negative regulator of Toll-like receptorinterleukin 1 receptor signaling. Nat. Immunol. 4: 920-927.
21. Riva, F., E. Bonavita, E. Barbati, M. Muzio, A. Mantovani, and C. Garlanda. 2012. TIR8/SIGIRR is an interleukin-1 receptor/Toll like receptor family member with regulatory functions in inflammation and immunity. Front. Immunol. 3: 322.
22. Qin, J., Y. Qian, J. Yao, C. Grace, and X. Li. 2005. SIGIRR inhibits interleukin-1 receptor-and Toll-like receptor 4-mediated signaling through different mechanisms. J. Biol. Chem. 280: 25233-25241.
23. Thomassen, E., B. R. Renshaw, and J. E. Sims. 1999. Identification and characterization of SIGIRR, a molecule representing a novel subtype of the IL-1R superfamily. Cytokine 11: 389-399.
24. Gulen, M. F., Z. Kang, K. Bulek, W. Youzhong, T. W. Kim, Y. Chen, C. Z. Altuntas, K. Sass Bak-Jensen, M. J. McGeachy, J. S. Do, et al. 2010. The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation. Immunity 32: 54-66.
25. Batliwalla, F. M., W. Li, C. T. Ritchlin, X. Xiao, M. Brenner, T. Laragione, T. Shao, R. Durham, S. Kemshetti, E. Schwarz, et al. 2005. Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis. Mol. Med. 11: 21-29.
26. Russell, S. E., and P. T. Walsh. 2012. Sterile inflammation-do innate lymphoid cell subsets play a role? Front Immunol 3: 246.
27. Sutton, C. E., S. J. Lalor, C. M. Sweeney, C. F. Brereton, E. C. Lavelle, and K. H. Mills. 2009. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 31: 331-341.
28. van der Fits, L., S. Mourits, J. S. Voerman, M. Kant, L. Boon, J. D. Laman, F. Cornelissen, A. M. Mus, E. Florencia, E. P. Prens, and E. Lubberts. 2009. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J. Immunol. 182: 5836-5845.
29. Szeimies, R. M., M. J. Gerritsen, G. Gupta, J. P. Ortonne, S. Serresi, J. Bichel, J. H. Lee, T. L. Fox, and A. Alomar. 2004. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehiclecontrolled, clinical trial with histology. J. Am. Acad. Dermatol. 51: 547-555.
30. Geisse, J. K., P. Rich, A. Pandya, K. Gross, K. Andres, A. Ginkel, and M. Owens. 2002. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J. Am. Acad. Dermatol. 47: 390-398.
31. Gilliet, M., C. Conrad, M. Geiges, A. Cozzio, W. Thürlimann, G. Burg, F. O. Nestle, and R. Dummer. 2004. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch. Dermatol. 140: 1490-1495.
32. Wu, J. K., G. Siller, and G. Strutton. 2004. Psoriasis induced by topical imiquimod. Australas. J. Dermatol. 45: 47-50.
33. Hedrick, M. N., A. S. Lonsdorf, A. K. Shirakawa, C. C. Richard Lee, F. Liao, S. P. Singh, H. H. Zhang, A. Grinberg, P. E. Love, S. T. Hwang, and J. M. Farber. 2009. CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. J. Clin. Invest. 119: 2317-2329.
34. Lech, M., V. Skuginna, O. P. Kulkarni, J. Gong, T. Wei, R. W. Stark, C. Garlanda, A. Mantovani, and H. J. Anders. 2010. Lack of SIGIRR/TIR8 aggravates hydrocarbon oil-induced lupus nephritis. J. Pathol. 220: 596-607.
35. Gong, J., T. Wei, R. W. Stark, F. Jamitzky, W. M. Heckl, H. J. Anders, M. Lech, and S. C. Rössle. 2010. Inhibition of Toll-like receptors TLR4 and 7 signaling pathways by SIGIRR: a computational approach. J. Struct. Biol. 169: 323-330.
36. Mabuchi, T., T. Takekoshi, and S. T. Hwang. 2011. Epidermal CCR6+ gd T cells are major producers of IL-22 and IL-17 in a murine model of psoriasiform dermatitis. J. Immunol. 187: 5026-5031.
37. Cua, D. J., and C. M. Tato. 2010. Innate IL-17-producing cells: the sentinels of the immune system. Nat. Rev. Immunol. 10: 479-489.
38. Shepherd, J., M. C. Little, and M. J. Nicklin. 2004. Psoriasis-like cutaneous inflammation in mice lacking interleukin-1 receptor antagonist. J. Invest. Dermatol. 122: 665-669.
39. Wang, Y., H. Gao, C. M. Loyd, W. Fu, D. Diaconu, S. Liu, K. D. Cooper, T. S. McCormick, D. I. Simon, and N. L. Ward. 2012. Chronic skin-specific inflammation promotes vascular inflammation and thrombosis. J. Invest. Dermatol. 132: 2067-2075.
40. Bozza, S., T. Zelante, S. Moretti, P. Bonifazi, A. DeLuca, C. D'Angelo, G. Giovannini, C. Garlanda, L. Boon, F. Bistoni, et al. 2008. Lack of Toll IL-1R8 exacerbates Th17 cell responses in fungal infection. J. Immunol. 180: 4022-4031.
41. Van Belle, A. B., M. de Heusch, M. M. Lemaire, E. Hendrickx, G. Warnier, K. Dunussi-Joannopoulos, L. A. Fouser, J. C. Renauld, and L. Dumoutier. 2012. IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J. Immunol. 188: 462-469.
42. Johnston, A., Y. Fritz, S. M. Dawes, D. Diaconu, P. M. Al-Attar, A. M. Guzman, C. S. Chen, W. Fu, J. E. Gudjonsson, T. S. McCormick, and N. L. Ward. 2013. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J. Immunol. 190: 2252-2262.
43. El Malki, K., S. H. Karbach, J. Huppert, M. Zayoud, S. Reissig, R. Schüler, A. Nikolaev, K. Karram, T. Münzel, C. R. Kuhlmann, et al. 2013. An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor a signaling. J. Invest. Dermatol. 133: 441-451.